A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease

Neurology

Volumn 90, Issue 21, 2018, Pages E1889-E1897

  Cummings, Jeffrey L ^a   Cohen, Sharon ^b   Van Dyck, Christopher H ^c   Brody, Mark ^d   Curtis, Craig ^e   Cho, William ^f   Ward, Michael ^f   Friesenhahn, Michel ^f   Brunstein, Flavia ^f   Quartino, Angelica ^f   Honigberg, Lee A ^f   Fuji, Reina N ^f   Clayton, David ^f   Mortensen, Deborah ^f   Ho, Carole ^f   Paul, Robert ^f   Rabe, Christina ^g,h  

^a CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

^b Toronto Memory Program   (Canada)

^c Massachusetts Gen H   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Delray Beach   (United States)

^f GENENTECH INC   (United States)

^g Roche Diagnostics ^*  (United States)

^h ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CHOLINESTERASE INHIBITOR; CRENEZUMAB; MEMANTINE; PLACEBO; MONOCLONAL ANTIBODY;

ADULT; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL DEMENTIA RATING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FAINTNESS; FALLING; FEMALE; HEADACHE; HUMAN; INFUSION RELATED REACTION; INJECTION SITE REACTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MINIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; STEADY STATE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; CLINICAL TRIAL; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; TREATMENT OUTCOME;

EID: 85052913439     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Alzheimer's Association Report. Alzheimer's disease facts and figures. Alzheimers Dement 2017;13:325-373.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002;297:353-356.
3. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007;8:101-112.
4. Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer's disease: An emperor in need of clothes. Nat Neurosci 2012;15:349.
5. Wang ZX, Tan L, Liu J, Yu JT. The essential role of soluble Aβ oligomers in Alzheimer's disease. Mol Neurobiol 2016;53:1905.
6. Adolfsson O, Pihlgren M, Toni N, et al. An effector-reduced anti-β-amyloid (Aβ) antibody with unique binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci 2012;32:9677-9689.
7. Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol 2015;14:388-405.
8. Xing B, Bachstetter AD, Van Eldik LJ. Microglial p38alpha MAPK is critical for LPSinduced neuron degeneration, through a mechanism involving TNFalpha. Mol Neurodegener 2011;6:84.
9. Fuller JP, Stavenhagen JB, Teeling JL. New roles for Fc receptors in neurodegeneration: The impact on Immunotherapy for Alzheimer's disease. Front Neurosci 2014;8:235.
10. Salloway S, Sperling R, Fox NC, et al. Two Phase 3 trials of bapineuzumab in mild-tomoderate Alzheimer's disease. N Engl J Med 2014;370:322-333.
11. Lasser R, Ostrowitzki S, Scheltens P, et al. Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: results fromSCarlet RoAD: A global, multicenter trial. Alzheimers Dement 2015;11:P331-P332.
12. Wilcock DM, Alamed J, Gottschall PE, et al. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 2006;26:5340-5346.
13. Ultsch M, Li B, Maurer T, et al. Structure of crenezumab complex with Aβ shows loss of β-hairpin. Sci Rep 2016;6:39374.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
15. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12: 189-198.
16. Sheikh RL, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clin Gerontol 1986;5:165-173.
17. O'Bryant SE, Waring SC, Cullum CM, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: A Texas Alzheimer's Research Consortium study. Arch Neurol 2008;65:1091-1095.
18. Berg L, Miller JP, Baty J, Rubin EH, Morris JC, Figiel G. Mild senile dementia of the Alzheimer type, 4: Evaluation of intervention. Ann Neurol 1992;31:242-249.
19. Sano M, Raman R, Emond J, et al. Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease. Alzheimer Dis Assoc Disord 2011;25:122-127.
20. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's Disease Assessment Scale that broaden its scope: The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S13-S21.
21. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
22. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S33-S39.
23. Bittner T, Zetterberg H, Teunissen CE, et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of beta-amyloid (1-42) in human cerebrospinal fluid. Alzheimers Dement 2016;12: 517-526.
24. Henley DB, Sundell KL, Sethuraman G, Schneider LS. Adverse events and dropouts in Alzheimer's disease studies: What can we learn? Alzheimers Dement 2015;11: 24-31.
25. Doody RS, Farlow M, Aisen PS. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med 2014;370:1460.
26. Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 2016;537:50-56.
27. Sevigny J, Chiao P, Williams L, Miao X, O'Gorman J. Randomized, double-blind, phase 1b study of BIIB037, an anti-amyloid beta monocloncal antibody, in patients with prodromal or mild Alzheimer's disease. Neurodegener Dis 2015;15 (suppl 1):311.
28. Lasser R, Ostrowitzki S, Scheltens P, et al. Efficacy and safety of gantenerumab from the phase 3 SCarlet RoAD trial, a study of gantenerumab in patients with prodromal AD. JPAD 2015;2:275.
29. Chong CP, Street PR. Pneumonia in the elderly: A review of the epidemiology, pathogenesis, microbiology, and clinical features. South Med J 2008;101:1141-1145; quiz 1132, 1179.